Suppr超能文献

原发性肺癌脑转移瘤的治疗

Treatment of brain metastases from primary lung cancer.

作者信息

Ryan G F, Ball D L, Smith J G

机构信息

Peter MacCallum Cancer Institute, Melbourne, Victoria, Australia.

出版信息

Int J Radiat Oncol Biol Phys. 1995 Jan 15;31(2):273-8. doi: 10.1016/0360-3016(93)E0073-F.

Abstract

PURPOSE

A retrospective study of patients treated at the Peter MacCallum Cancer Institute for brain metastases from primary carcinoma of the lung is presented.

METHODS AND MATERIALS

The medical records of 416 patients with the diagnosis of primary carcinoma of the lung who presented with, or subsequently developed, brain metastases during the period January 1984 to December 1987 were reviewed. Information on a number of factors of potential prognostic significance (sex, age, histology, performance status and interval between diagnosis of the primary and brain metastases) was collected. Details of surgery, radiation and steroid usage were recorded, and any steroid side effects documented. Survival was calculated from the date of diagnosis of brain metastases. Stepwise regression based on Cox's proportional hazards model was used to determine significant prognostic factors affecting survival. Patients with and without steroid side effects were compared using Yates's corrected chi-square test.

RESULTS

The overall estimated median survival was only 3.3 months (95% confidence interval 2.9-3.7 months). Only two factors were found to be associated with a significantly improved survival--surgical intervention and good performance status. After taking these two factors into account, the dose of radiation used (< 30 Gy or > or = 30 Gy) did not influence survival. There was a 3% incidence of gastric bleeding or perforation in patients taking steroids, with a 40% fatality rate. Predisposing factors to gastric side effects were a prior history of peptic ulcer and/or aspirin or nonsteroidal anti-inflammatory drug consumption.

CONCLUSION

Radiation of brain metastases from primary lung cancer results in modest survival benefit. Radiation dose (< 30 Gy or > or = 30 Gy) is not a significant determinant of survival. Other treatment modifications, such as concurrent radiation and chemotherapy, should be explored. Steroids should be used with caution as fatal side effects can occur.

摘要

目的

对彼得·麦卡勒姆癌症研究所治疗的原发性肺癌脑转移患者进行回顾性研究。

方法与材料

回顾了1984年1月至1987年12月期间416例诊断为原发性肺癌且出现或随后发生脑转移的患者的病历。收集了一些具有潜在预后意义的因素(性别、年龄、组织学、体能状态以及原发性肿瘤诊断与脑转移之间的间隔时间)的信息。记录了手术、放疗和类固醇使用的详细情况,并记录了任何类固醇副作用。从脑转移诊断日期开始计算生存期。使用基于Cox比例风险模型的逐步回归来确定影响生存期的显著预后因素。使用Yates校正卡方检验比较有和没有类固醇副作用的患者。

结果

总体估计中位生存期仅为3.3个月(95%置信区间2.9 - 3.7个月)。仅发现两个因素与生存期显著改善相关——手术干预和良好的体能状态。在考虑这两个因素后,使用的放疗剂量(<30 Gy或≥30 Gy)不影响生存期。服用类固醇的患者中胃出血或穿孔的发生率为3%,死亡率为40%。胃副作用的诱发因素是消化性溃疡病史和/或服用阿司匹林或非甾体类抗炎药。

结论

原发性肺癌脑转移的放疗可带来适度的生存益处。放疗剂量(<30 Gy或≥30 Gy)不是生存期的重要决定因素。应探索其他治疗改进方法,如同步放疗和化疗。使用类固醇时应谨慎,因为可能会出现致命副作用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验